Login to Your Account



DOV Halts Ocinaplon Phase III To Check Liver Enzyme Status

By Aaron Lorenzo


Monday, August 29, 2005
Because of potential liver toxicity risks, DOV Pharmaceutical Inc. shut down a Phase III trial of its investigational anti-anxiety agent ocinaplon, a setback that could cause the company to drop the drug altogether. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription